Evidence map›Paper›PMID 41387009›Full record

ArticleBMJ open2025

Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the

Emily G McDonald, Matthew P Cheng, Joshua S Davis, Anna L Goodman, Patrick R Lawler, Julie Marsh, Dominik Mertz, Mical Paul, Jesús Rodriguez-Baño, Deborah M Siegal and 4 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06650501 (Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06650501 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2026 to 2030Enrolled300ConditionsStaphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream InfectionArmsDabigatran, Apixaban, edoxaban, Rivaroxaban
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Emily G McDonaldDepartment of Medicine, McGill University Health Centre, Montreal, Québec, Canada emily.mcdonald@mcgill.ca.ORCID http://orcid.org/0000-0003-0783-0624
Matthew P ChengMcGill University, Montreal, Québec, Canada.
Joshua S DavisThe University of Newcastle School of Medicine and Public Health, Callaghan, New South Wales, Australia.
Anna L GoodmanCentre for Clinical Infection and Diagnostics Research, Guy's and Saint Thomas' NHS Foundation Trust, London, UK.
Patrick R LawlerDepartment of Cardiology, McGill University Health Centre, Montreal, Québec, Canada.
Julie MarshThe University of Western Australia - Perth Campus, Perth, Western Australia, Australia.
Dominik MertzDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID http://orcid.org/0000-0003-4337-1613
Mical PaulTechnion Israel Institute of Technology, Haifa, Israel.
Jesús Rodriguez-BañoHospital Universitario Virgen Macarena, Seville, Spain.
Deborah M SiegalDepartment of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Steven Yc TongDepartment of Infectious Diseases, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-1368-8356
Genevieve WallsMiddlemore Hosp, Middlemore, UK.
Todd C LeeMcGill University Health Centre, Montreal, Québec, Canada.ORCID http://orcid.org/0000-0002-2267-4239
SNAP Global Trial Steering Committee

Funding

Clinical Impact of the Cefazolin Inoculum EffectR01AI173138 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Cesar Augusto Arias · 2023 to 2026
$2.6M
NIAID NIH HHS R01 AI173138
6 · The paper itself

Abstract

introductionMany patients receive oral anticoagulation for reduced stroke risk in atrial fibrillation or as treatment or prevention of venous thromboembolism. Oral factor Xa inhibitors (oral FXaI, eg, apixaban, edoxaban or rivaroxaban) are commonly prescribed for this indication. Dabigatran, an oral direct thrombin inhibitor, is similarly approved. In vitro and animal model evidence suggests that dabigatran also has direct effects on METHODS AND ANALYSIS: The ETHICS AND DISSEMINATION: The study is conditionally approved by the research ethics board of the McGill University Health Centre: identifier 2025-10900. Trial results will be published open access in a peer-reviewed journal and presented at a global infectious disease conference. The trial is registered at clinicaltrials.gov with the identifier NCT06650501. TRIAL REGISTRATION NUMBER: NCT0665050.

Indexed as

AnticoagulantsAntithrombinsBacteremiaDabigatranStaphylococcal InfectionsStaphylococcus aureusAnti-Bacterial AgentsClinical Trials, Phase IV as TopicFactor Xa InhibitorsHumansMulticenter Studies as TopicPragmatic Clinical Trials as TopicRandomized Controlled Trials as TopicAnti-Bacterial AgentsAnticoagulantsAntithrombinsDabigatranFactor Xa InhibitorsAnti-Bacterial AgentsBACTERIOLOGYMICROBIOLOGY

Identifiers

PMID41387009
PMCPMC12706227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.